| Code | CSB-RA004952MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody described in US10865247B2, targeting CD69, a C-type lectin receptor expressed on activated lymphocytes. CD69 functions as an early activation marker on T cells, B cells, NK cells, and other leukocyte populations, playing critical roles in immune cell retention, differentiation, and effector functions. This transmembrane protein regulates lymphocyte egress from lymphoid tissues through sphingosine-1-phosphate receptor modulation and participates in inflammatory responses. CD69 expression is associated with various pathological conditions including autoimmune diseases, allergic disorders, inflammatory bowel disease, and tumor-infiltrating lymphocyte populations in cancer microenvironments.
The reference antibody serves as a benchmark for developing high-quality research reagents that maintain comparable binding characteristics and specificity. This biosimilar antibody provides researchers with a reliable tool for investigating CD69-mediated immune regulation, studying lymphocyte activation dynamics, exploring therapeutic targeting strategies in autoimmune conditions, and characterizing immune cell phenotypes in disease models and clinical samples.
There are currently no reviews for this product.